MAPK4 and ovarian cancer: In another study, an anti-MUC1 aptamer was used to deliver tumor suppressor miR-29b to ovarian cancer cells, leading to decreased chemo-resistance and a significant inhibition of tumor growth possibly via attenuating phosphatase and tensin homolog (PTEN) and mitogen-activated protein kinases-4 (MAPK4) signaling [123].